HGH treatments

HGH injections therapy for Osteoporosis Treatment

For years after it was administered, growth hormone continued to reduce the risk of fractures and helped maintain bone density in postmenopausal women who had osteoporosis, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Osteoporosis is a progressive condition that causes the bones to become weak and […]

HGH for Idiopathic Short Stature

INTRODUCTION Treatment of children and adolescents with growth hormone for idiopathic short stature (ISS) is controversial for two reasons. First, the response to growth hormone is highly variable, probably because of the heterogeneous endocrinologic profile in children with ISS, and those children who respond to growth hormone treatment may have only modest increases in linear […]

Evolving Latest Treatments For Growth Hormone Deficiency In Children

Significant progress has been made in the diagnosis and management of short stature since the introduction of growth hormone therapy half a century ago. Growth hormone has been approved for a range of conditions resulting in short stature beyond growth hormone deficiency, including chronic kidney dysfunction and Turner syndrome. In addition to biological causes of […]

Somapacitan Novo Nordisk : Long acting Human growth hormone injection

Novo Nordisk’s somapacitan is a long-acting human growth hormone derivative being developed to treat growth hormone deficiency. Credit: Novo Nordisk A/S. demonstrated safety, efficacy and tolerability comparable to that of once-daily Norditropin (somatropin) after one year. One of areas of focus among biopharmaceutical companies currently is having a treatment for growth hormone deficiency that reduces […]

Somapacitan Mechanism Of Action

Somapacitan is under investigation in clinical trial NCT01706783 (A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency). Abstract Somapacitan is a long‐acting growth hormone (GH) intended for once‐weekly subcutaneous administration. As for GH, the […]

Role of IGF-1 in Parkinsons development

  Increasing evidence links insulin-like growth factor 1 (IGF-1) deficiency to the development and progression of Parkinson’s disease, a review study said. Estrogen, the female sex hormone thought to hold potential beneficial effects against Parkinson’s, or PD, may exert its protective actions via IGF-1, the researchers said. To be able to test our hypothesis if […]

Scroll to top